EP-Link Co., Ltd. provides clinical trial and clinical research support services based on relationships of trust with all parties with whom it interacts, including medical institutions, pharmaceutical companies, clinical trial participants, and other stakeholders.
In fulfilling its social mission of supporting the development of new pharmaceuticals and medical technologies, EP-Link strives to build and maintain positive relationships founded on mutual understanding and trust, while respecting the dignity and individuality of every person.
At the same time, certain conduct directed toward EP-Link employees, such as abusive language, intimidation, degrading or humiliating remarks, defamation, or unreasonable and excessive demands, can undermine employees' working environment and interfere with the provision of appropriate services.
EP-Link values feedback and requests from all stakeholders and is committed to responding sincerely and in good faith. However, to protect the safety, dignity, and human rights of its employees, EP-Link will take a firm organizational approach against abusive behavior by customers.
Furthermore, should any EP-Link employee engage in similar inappropriate conduct toward any stakeholder, EP-Link will confirm the relevant facts and take appropriate action in accordance with its internal rules, policies, and other applicable regulations.
Based on the concept of customer harassment described by Japan's Ministry of Health, Labour and Welfare, EP-Link defines abusive behavior as demands or conduct by customers that exceed socially acceptable norms and adversely affect the working environment of employees.
Examples include, but are not limited to, the following:
These examples are illustrative only and are not intended to be exhaustive.
When EP-Link determines, after considering the relevant facts and circumstances, that abusive behavior has occurred, EP-Link may take one or more of the following measures as appropriate:
Furthermore, should any EP-Link employee engage in similar inappropriate conduct toward any stakeholder, EP-Link will confirm the relevant facts and take appropriate action in accordance with its internal rules, policies, and other applicable regulations.
EP-Link remains committed to maintaining a workplace where employees can work safely and with peace of mind.
While continuing to value trust-based relationships with all stakeholders, EP-Link will strive to provide high-quality clinical trial and clinical research support services.
We appreciate your understanding and cooperation.
Hironao Nakajima
Representative Director
October 1, 2026